| NCT Number | NCT05473299 |
| Lead Sponsor | Xeltis |
| Conditions | End-stage Renal Disease |
| Enrollment | 120 participants |
| Start Date | 2022-11-04 |
| Primary Completion | 2025-06-23 (estimated) |
| Study Completion | 2029-12-31 (estimated) |
| Updated on ClinicalTrials.gov | 2025-07-18 |